Werewolf Therapeutics (HOWL) Competitors $0.90 +0.03 (+3.34%) Closing price 04:00 PM EasternExtended Trading$0.91 +0.01 (+1.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL vs. LRMR, NBTX, PBYI, CYBN, ACRS, EPRX, NLTX, ADCT, FATE, and NKTXShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Larimar Therapeutics (LRMR), Nanobiotix (NBTX), Puma Biotechnology (PBYI), Cybin (CYBN), Aclaris Therapeutics (ACRS), Eupraxia Pharmaceuticals (EPRX), Neoleukin Therapeutics (NLTX), ADC Therapeutics (ADCT), Fate Therapeutics (FATE), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Larimar Therapeutics Nanobiotix Puma Biotechnology Cybin Aclaris Therapeutics Eupraxia Pharmaceuticals Neoleukin Therapeutics ADC Therapeutics Fate Therapeutics Nkarta Werewolf Therapeutics (NASDAQ:HOWL) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability. Is HOWL or LRMR more profitable? Larimar Therapeutics has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Larimar Therapeutics' return on equity of -35.87% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics-578.80% -58.83% -38.45% Larimar Therapeutics N/A -35.87%-32.37% Which has stronger earnings & valuation, HOWL or LRMR? Larimar Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.89M21.40-$37.37M-$1.66-0.54Larimar TherapeuticsN/AN/A-$36.95M-$1.30-2.28 Which has more risk & volatility, HOWL or LRMR? Werewolf Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Do analysts prefer HOWL or LRMR? Werewolf Therapeutics currently has a consensus target price of $9.00, indicating a potential upside of 900.00%. Larimar Therapeutics has a consensus target price of $19.63, indicating a potential upside of 560.77%. Given Werewolf Therapeutics' higher probable upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Larimar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Do insiders & institutionals have more ownership in HOWL or LRMR? 64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 21.1% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to HOWL or LRMR? In the previous week, Larimar Therapeutics had 4 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 8 mentions for Larimar Therapeutics and 4 mentions for Werewolf Therapeutics. Larimar Therapeutics' average media sentiment score of 0.59 beat Werewolf Therapeutics' score of -0.19 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer HOWL or LRMR? Larimar Therapeutics received 12 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. Likewise, 71.88% of users gave Larimar Therapeutics an outperform vote while only 70.83% of users gave Werewolf Therapeutics an outperform vote. CompanyUnderperformOutperformWerewolf TherapeuticsOutperform Votes3470.83% Underperform Votes1429.17% Larimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% SummaryLarimar Therapeutics beats Werewolf Therapeutics on 14 of the 18 factors compared between the two stocks. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.34M$6.85B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-0.597.5022.7518.82Price / Sales21.40257.30403.97106.68Price / CashN/A65.8538.1834.62Price / Book0.296.576.794.33Net Income-$37.37M$143.37M$3.22B$247.85M7 Day Performance1.04%3.64%2.30%2.73%1 Month Performance-1.36%6.02%3.64%3.38%1 Year Performance-85.20%-2.12%16.87%5.82% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics2.2705 of 5 stars$0.90+3.3%$9.00+900.0%-85.5%$40.34M$1.89M-0.5940News CoverageLRMRLarimar Therapeutics1.7253 of 5 stars$2.35+0.9%$19.63+735.1%-61.1%$150.47MN/A-2.0430Earnings ReportUpcoming EarningsOptions VolumeAnalyst RevisionNews CoverageNBTXNanobiotix1.9638 of 5 stars$3.19+1.3%$8.00+150.8%-44.8%$150.35M$-11,609,000.000.00100Gap UpPBYIPuma Biotechnology3.8353 of 5 stars$2.98-0.7%$7.00+134.9%-37.8%$147.84M$230.47M6.21200Upcoming EarningsAnalyst RevisionNews CoverageCYBNCybin2.0245 of 5 stars$6.87-1.7%$86.00+1,151.8%N/A$147.55MN/A-1.5750News CoverageACRSAclaris Therapeutics3.1776 of 5 stars$1.36+1.5%$11.67+757.8%+9.5%$147.26M$18.72M-2.62100Upcoming EarningsShort Interest ↓News CoveragePositive NewsEPRXEupraxia Pharmaceuticals2.916 of 5 stars$4.04+6.0%$10.50+159.9%+48.3%$144.83MN/A-5.6129Positive NewsNLTXNeoleukin TherapeuticsN/A$15.41+0.3%N/A-56.5%$144.82MN/A-4.9590High Trading VolumeADCTADC Therapeutics1.4194 of 5 stars$1.46+9.8%$7.75+430.8%-69.1%$144.81M$70.84M-0.61310Upcoming EarningsGap UpFATEFate Therapeutics3.8427 of 5 stars$1.25-2.3%$5.43+334.3%-69.7%$143.26M$13.63M-0.76550Upcoming EarningsNews CoverageNKTXNkarta2.7838 of 5 stars$2.01-4.7%$14.86+639.2%-72.6%$142.63MN/A-1.07140Upcoming EarningsPositive News Related Companies and Tools Related Companies Larimar Therapeutics Alternatives Nanobiotix Alternatives Puma Biotechnology Alternatives Cybin Alternatives Aclaris Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Neoleukin Therapeutics Alternatives ADC Therapeutics Alternatives Fate Therapeutics Alternatives Nkarta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOWL) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOWL Stock Free HOWL Stock Alerts